Abstract, Snapshot, Market Analysis & Market Definition: Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
Bladder cancer is the tenth most common cancer worldwide and the sixth most common cancer in the US. In 2018, there were over half a million new cases of bladder cancer diagnosed, with around 200,000 deaths from the disease globally. In the US, an estimated 80,470 cases of bladder cancer were diagnosed in 2019, with around 12,500 locally advanced or metastatic cases presented annually. UC accounts for about 90% of all bladder cancer. UC becomes harder to treat as it advances, spreading through the layers of the bladder wall.
In 2020, the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2029, with a CAGR of xx% during 2020-2029. This report focuses on the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs development in United States, Europe and China.
Market Segmentation, Outlook & Regional Insights: Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Segmentation by Product Type: Breakdown of data from year 2014 to 2020 and forecast until 2029:
- Afinitor (Everolimus)
- Avastin (Bevacizumab)
- Cabomety (Cabozantinib)
- Inlyta (Axitinib)
- Nexavar (Sorafenib)
- Proleukin (Aldesleukin)
- Torisel (Temsirolimus)
- Sutent (Sunitinib)
- Votrient (Pazopanib)
Segmentation by Application: Breakdown of data from year 2014 to 2019 and forecast until 2025:
Market segment by Regions/Countries, this report covers
- United States
- Southeast Asia
- Central & South America
Key Players, Recent Developments & Sector Viewpoints: Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
In August 2020, Samsung Bioepis NL B.V. received marketing authorization valid throughout the European Union for Aybintio which is a cancer medicine that is used to treat adults with the below cancers:
Cancer of the colon (large bowel) or the rectum, when it has spread to other parts of the body;
Breast cancer that has spread to other parts of the body;
A type of lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Aybintio can be used in non-small cell lung cancer unless it originates in cells of a particular type (called squamous cells);
Cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere;
Cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb and the peritoneum, the membrane that lines the abdomen) that is advanced or has come back after treatment;
Cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or spread to other parts of the body.
Aybintio is used in combination with other cancer medicines, depending on the nature of any previous treatments or the presence of mutations (genetic changes) in the cancer that affect how well particular medicines work. The reference medicine for Aybintio is Avastin.
Samsung Bioepis’ Aybintio is expected to heat up biosimilars competition referencing Roche’s Avastin (ingredient: bevacizumab) in Europe.
In Jun 2020, FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma. First and only FDA-approved immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III study. Priority review completed under FDA’s Real-Time Oncology Review (RTOR) pilot program, following receipt of Breakthrough Therapy Designation. EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.
The FDA previously approved BAVENCIO under the accelerated approval program in 2017 for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, based on tumor response rate and duration of response. Continued approval was contingent upon verification of clinical benefit, which was demonstrated in JAVELIN Bladder 100. The FDA has now converted the accelerated approval to full approval.
This approval for BAVENCIO, has the opportunity to fundamentally shift the standard of care in the first-line setting of advanced bladder cancer. The focus will be to work closely with the GU community to ensure that this novel and potentially life-changing treatment paradigm is rapidly integrated into clinical practice.
The alliance is committed to providing patient access and reimbursement support through its CoverOne® program to patients who have been prescribed BAVENCIO. This program provides a spectrum of patient access and reimbursement support services intended to help US patients prescribed BAVENCIO receive appropriate access.
Overview and General Information of the drugs researched in the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Report
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Bevacizumab (Avastin) gained FDA approval in 2004 for specific types of cancer and became the first antiangiogenic agent introduced to the market. It is a humanized monoclonal IgG antibody and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer.
Avastin sold 7.07 billion Swiss francs ($7.46 billion) around the world in 2019. Among them, one-fourth, or 1.79 billion Swiss franc sales, came from Europe.
Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI). As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.
In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).7 Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Covered: Exhaustive Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
1. Market size (sales, revenue and growth rate) of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry.
3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry.
4. Market size (sales, revenue) forecast by regions and countries from 2020 to 2029 of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry.